Testicular tumors: Oncologic imaging and diagnosis

Jay Heiken, Dennis M. Balfe, Bruce L. McClennan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The extreme radiosensitivity of testicular seminomas plus recent advances in chemotherapy for nonseminomatous tumors and for advanced seminomas have made long term survival possible in the large majority of patients with testis cancer. Since choice of therapy is determined by tumor histology and extent of disease, accurate clinical staging is critical. Computed tomography (CT) of the abdomen and chest is the imaging procedure of choice for staging testis cancer. Clinical staging accuracy of 80 to 90% can be achieved using CT in combination with radioimmunoassays for β-HCG and AFP. Ultrasonography (US), while less sensitive and specific than CT for determining nodal status, may be useful in thin patients with sparse retroperitoneal fat; in addition US may play an important role in detecting occult testicular neoplasms and in assessing primary tumor extent within the scrotum. Lymphangiography should be reserved for Stage I patients in whom elective treatment of the retroperitoneum is not planned. Follow-up should include serial radioimmunoassays for serum AFP and β-HCG and periodic CT examinations of the abdomen and chest. Technical improvements in CT scanners and further experience with the use of tumor markers should help refine our ability to stage and manage patients with testicular tumors. In addition, nuclear magnetic resonance (NMR) imaging and radionuclide imaging following injection of radioactively labelled antibodies to AFP and β-HCG are new techniques which offer great promise for the future.

Original languageEnglish (US)
Pages (from-to)275-287
Number of pages13
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume10
Issue number2
DOIs
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Testicular Neoplasms
tumors
tomography
Tomography
Seminoma
radioimmunoassay
testes
abdomen
Abdomen
chest
Radioimmunoassay
Ultrasonography
Thorax
X-Ray Computed Tomography Scanners
Lymphography
Neoplasms
Scrotum
cancer
Intra-Abdominal Fat
Radiation Tolerance

Keywords

  • Clinical staging
  • Computed tomography (CT)
  • Diagnostic imaging
  • Germ cell tumor
  • Lymphangiography
  • Seminoma
  • Testis cancer
  • Treatment
  • Ultrasonography

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Testicular tumors : Oncologic imaging and diagnosis. / Heiken, Jay; Balfe, Dennis M.; McClennan, Bruce L.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 10, No. 2, 01.01.1984, p. 275-287.

Research output: Contribution to journalArticle

Heiken, Jay ; Balfe, Dennis M. ; McClennan, Bruce L. / Testicular tumors : Oncologic imaging and diagnosis. In: International Journal of Radiation Oncology, Biology, Physics. 1984 ; Vol. 10, No. 2. pp. 275-287.
@article{914d9690e2ff426791a9d394abff5484,
title = "Testicular tumors: Oncologic imaging and diagnosis",
abstract = "The extreme radiosensitivity of testicular seminomas plus recent advances in chemotherapy for nonseminomatous tumors and for advanced seminomas have made long term survival possible in the large majority of patients with testis cancer. Since choice of therapy is determined by tumor histology and extent of disease, accurate clinical staging is critical. Computed tomography (CT) of the abdomen and chest is the imaging procedure of choice for staging testis cancer. Clinical staging accuracy of 80 to 90{\%} can be achieved using CT in combination with radioimmunoassays for β-HCG and AFP. Ultrasonography (US), while less sensitive and specific than CT for determining nodal status, may be useful in thin patients with sparse retroperitoneal fat; in addition US may play an important role in detecting occult testicular neoplasms and in assessing primary tumor extent within the scrotum. Lymphangiography should be reserved for Stage I patients in whom elective treatment of the retroperitoneum is not planned. Follow-up should include serial radioimmunoassays for serum AFP and β-HCG and periodic CT examinations of the abdomen and chest. Technical improvements in CT scanners and further experience with the use of tumor markers should help refine our ability to stage and manage patients with testicular tumors. In addition, nuclear magnetic resonance (NMR) imaging and radionuclide imaging following injection of radioactively labelled antibodies to AFP and β-HCG are new techniques which offer great promise for the future.",
keywords = "Clinical staging, Computed tomography (CT), Diagnostic imaging, Germ cell tumor, Lymphangiography, Seminoma, Testis cancer, Treatment, Ultrasonography",
author = "Jay Heiken and Balfe, {Dennis M.} and McClennan, {Bruce L.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1016/0360-3016(84)90014-2",
language = "English (US)",
volume = "10",
pages = "275--287",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Testicular tumors

T2 - Oncologic imaging and diagnosis

AU - Heiken, Jay

AU - Balfe, Dennis M.

AU - McClennan, Bruce L.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - The extreme radiosensitivity of testicular seminomas plus recent advances in chemotherapy for nonseminomatous tumors and for advanced seminomas have made long term survival possible in the large majority of patients with testis cancer. Since choice of therapy is determined by tumor histology and extent of disease, accurate clinical staging is critical. Computed tomography (CT) of the abdomen and chest is the imaging procedure of choice for staging testis cancer. Clinical staging accuracy of 80 to 90% can be achieved using CT in combination with radioimmunoassays for β-HCG and AFP. Ultrasonography (US), while less sensitive and specific than CT for determining nodal status, may be useful in thin patients with sparse retroperitoneal fat; in addition US may play an important role in detecting occult testicular neoplasms and in assessing primary tumor extent within the scrotum. Lymphangiography should be reserved for Stage I patients in whom elective treatment of the retroperitoneum is not planned. Follow-up should include serial radioimmunoassays for serum AFP and β-HCG and periodic CT examinations of the abdomen and chest. Technical improvements in CT scanners and further experience with the use of tumor markers should help refine our ability to stage and manage patients with testicular tumors. In addition, nuclear magnetic resonance (NMR) imaging and radionuclide imaging following injection of radioactively labelled antibodies to AFP and β-HCG are new techniques which offer great promise for the future.

AB - The extreme radiosensitivity of testicular seminomas plus recent advances in chemotherapy for nonseminomatous tumors and for advanced seminomas have made long term survival possible in the large majority of patients with testis cancer. Since choice of therapy is determined by tumor histology and extent of disease, accurate clinical staging is critical. Computed tomography (CT) of the abdomen and chest is the imaging procedure of choice for staging testis cancer. Clinical staging accuracy of 80 to 90% can be achieved using CT in combination with radioimmunoassays for β-HCG and AFP. Ultrasonography (US), while less sensitive and specific than CT for determining nodal status, may be useful in thin patients with sparse retroperitoneal fat; in addition US may play an important role in detecting occult testicular neoplasms and in assessing primary tumor extent within the scrotum. Lymphangiography should be reserved for Stage I patients in whom elective treatment of the retroperitoneum is not planned. Follow-up should include serial radioimmunoassays for serum AFP and β-HCG and periodic CT examinations of the abdomen and chest. Technical improvements in CT scanners and further experience with the use of tumor markers should help refine our ability to stage and manage patients with testicular tumors. In addition, nuclear magnetic resonance (NMR) imaging and radionuclide imaging following injection of radioactively labelled antibodies to AFP and β-HCG are new techniques which offer great promise for the future.

KW - Clinical staging

KW - Computed tomography (CT)

KW - Diagnostic imaging

KW - Germ cell tumor

KW - Lymphangiography

KW - Seminoma

KW - Testis cancer

KW - Treatment

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=0021262811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021262811&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(84)90014-2

DO - 10.1016/0360-3016(84)90014-2

M3 - Article

C2 - 6200463

AN - SCOPUS:0021262811

VL - 10

SP - 275

EP - 287

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -